Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors

Ji Tae Kim, Jing Li, Eun Ryoung Jang, Pat Gulhati, Piotr G. Rychahou, Dana L. Napier, Chi Wang, Heidi L. Weiss, Eun Y. Lee, Lowell Anthony, Courtney Townsend, Chunming Liu, B. Mark Evers

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Carcinoid tumors are rare neuroendocrine tumors (NETs) that are increasing in incidence. Mutation and altered expression of Wnt/β-catenin signaling components have been described in many tumors but have not been well-studied in NETs. Here, we observed accumulation of β-catenin in the cytoplasm and/or nucleus in 25% of clinical NET tissues. By mutational analysis, the mutations of β-catenin (I35S) and APC (E1317Q, T1493T) were identified in NET cells and the tissues. Expression of representative Wnt inhibitors was absent or markedly decreased in BON, a human pancreatic carcinoid cell line; treatment with 5-aza-2′-deoxycytidine (5-aza-CdR) increased expression levels of the Wnt inhibitors. Methylation analyses demonstrated that CpG islands of SFRP-1 and Axin-2 were methylated, whereas the promoters of DKK-1, DKK-3 and WIF-1 were unmethylated in four NET cells. Aberrant methylation of SFRP-1 was particularly observed in most of clinical NET tissues. In addition, the repression of these unmethylated genes was associated with histone H3 lysine 9 dimethylation (H3K9me2) in BON cells. Together, 5-aza-CdR treatment inhibited cell proliferation and decreased the protein levels of H3K9me2 and G9a. Moreover, a novel G9a inhibitor, UNC0638, suppressed BON cell proliferation through inhibition of Wnt/β-catenin pathway. Overexpression of the inhibitory genes, particularly SFRP-1 and WIF-1 in BON cells, resulted in suppression of anchorage-independent growth and inhibition of tumor growth in mice. Our findings suggest that aberrant Wnt/β-catenin signaling, through either mutations or epigenetic silencing of Wnt antagonists, contributes to the pathogenesis and growth of NETs and have important clinical implications for the prognosis and treatment of NETs.

Original languageEnglish (US)
Pages (from-to)953-961
Number of pages9
JournalCarcinogenesis
Volume34
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Catenins
Neuroendocrine Tumors
Epigenomics
Neuroendocrine Cells
decitabine
Carcinoid Tumor
Methylation
Mutation
Growth
Cell Proliferation
CpG Islands
Wnt Signaling Pathway
Histones
Genes
Lysine
Neoplasms
Cytoplasm
Cell Line
Incidence

ASJC Scopus subject areas

  • Cancer Research

Cite this

Kim, J. T., Li, J., Jang, E. R., Gulhati, P., Rychahou, P. G., Napier, D. L., ... Evers, B. M. (2013). Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors. Carcinogenesis, 34(5), 953-961. https://doi.org/10.1093/carcin/bgt018

Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors. / Kim, Ji Tae; Li, Jing; Jang, Eun Ryoung; Gulhati, Pat; Rychahou, Piotr G.; Napier, Dana L.; Wang, Chi; Weiss, Heidi L.; Lee, Eun Y.; Anthony, Lowell; Townsend, Courtney; Liu, Chunming; Evers, B. Mark.

In: Carcinogenesis, Vol. 34, No. 5, 05.2013, p. 953-961.

Research output: Contribution to journalArticle

Kim, JT, Li, J, Jang, ER, Gulhati, P, Rychahou, PG, Napier, DL, Wang, C, Weiss, HL, Lee, EY, Anthony, L, Townsend, C, Liu, C & Evers, BM 2013, 'Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors', Carcinogenesis, vol. 34, no. 5, pp. 953-961. https://doi.org/10.1093/carcin/bgt018
Kim, Ji Tae ; Li, Jing ; Jang, Eun Ryoung ; Gulhati, Pat ; Rychahou, Piotr G. ; Napier, Dana L. ; Wang, Chi ; Weiss, Heidi L. ; Lee, Eun Y. ; Anthony, Lowell ; Townsend, Courtney ; Liu, Chunming ; Evers, B. Mark. / Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors. In: Carcinogenesis. 2013 ; Vol. 34, No. 5. pp. 953-961.
@article{b1ff31018b7d4e3e87c5ef13ac3c1841,
title = "Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors",
abstract = "Carcinoid tumors are rare neuroendocrine tumors (NETs) that are increasing in incidence. Mutation and altered expression of Wnt/β-catenin signaling components have been described in many tumors but have not been well-studied in NETs. Here, we observed accumulation of β-catenin in the cytoplasm and/or nucleus in 25{\%} of clinical NET tissues. By mutational analysis, the mutations of β-catenin (I35S) and APC (E1317Q, T1493T) were identified in NET cells and the tissues. Expression of representative Wnt inhibitors was absent or markedly decreased in BON, a human pancreatic carcinoid cell line; treatment with 5-aza-2′-deoxycytidine (5-aza-CdR) increased expression levels of the Wnt inhibitors. Methylation analyses demonstrated that CpG islands of SFRP-1 and Axin-2 were methylated, whereas the promoters of DKK-1, DKK-3 and WIF-1 were unmethylated in four NET cells. Aberrant methylation of SFRP-1 was particularly observed in most of clinical NET tissues. In addition, the repression of these unmethylated genes was associated with histone H3 lysine 9 dimethylation (H3K9me2) in BON cells. Together, 5-aza-CdR treatment inhibited cell proliferation and decreased the protein levels of H3K9me2 and G9a. Moreover, a novel G9a inhibitor, UNC0638, suppressed BON cell proliferation through inhibition of Wnt/β-catenin pathway. Overexpression of the inhibitory genes, particularly SFRP-1 and WIF-1 in BON cells, resulted in suppression of anchorage-independent growth and inhibition of tumor growth in mice. Our findings suggest that aberrant Wnt/β-catenin signaling, through either mutations or epigenetic silencing of Wnt antagonists, contributes to the pathogenesis and growth of NETs and have important clinical implications for the prognosis and treatment of NETs.",
author = "Kim, {Ji Tae} and Jing Li and Jang, {Eun Ryoung} and Pat Gulhati and Rychahou, {Piotr G.} and Napier, {Dana L.} and Chi Wang and Weiss, {Heidi L.} and Lee, {Eun Y.} and Lowell Anthony and Courtney Townsend and Chunming Liu and Evers, {B. Mark}",
year = "2013",
month = "5",
doi = "10.1093/carcin/bgt018",
language = "English (US)",
volume = "34",
pages = "953--961",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors

AU - Kim, Ji Tae

AU - Li, Jing

AU - Jang, Eun Ryoung

AU - Gulhati, Pat

AU - Rychahou, Piotr G.

AU - Napier, Dana L.

AU - Wang, Chi

AU - Weiss, Heidi L.

AU - Lee, Eun Y.

AU - Anthony, Lowell

AU - Townsend, Courtney

AU - Liu, Chunming

AU - Evers, B. Mark

PY - 2013/5

Y1 - 2013/5

N2 - Carcinoid tumors are rare neuroendocrine tumors (NETs) that are increasing in incidence. Mutation and altered expression of Wnt/β-catenin signaling components have been described in many tumors but have not been well-studied in NETs. Here, we observed accumulation of β-catenin in the cytoplasm and/or nucleus in 25% of clinical NET tissues. By mutational analysis, the mutations of β-catenin (I35S) and APC (E1317Q, T1493T) were identified in NET cells and the tissues. Expression of representative Wnt inhibitors was absent or markedly decreased in BON, a human pancreatic carcinoid cell line; treatment with 5-aza-2′-deoxycytidine (5-aza-CdR) increased expression levels of the Wnt inhibitors. Methylation analyses demonstrated that CpG islands of SFRP-1 and Axin-2 were methylated, whereas the promoters of DKK-1, DKK-3 and WIF-1 were unmethylated in four NET cells. Aberrant methylation of SFRP-1 was particularly observed in most of clinical NET tissues. In addition, the repression of these unmethylated genes was associated with histone H3 lysine 9 dimethylation (H3K9me2) in BON cells. Together, 5-aza-CdR treatment inhibited cell proliferation and decreased the protein levels of H3K9me2 and G9a. Moreover, a novel G9a inhibitor, UNC0638, suppressed BON cell proliferation through inhibition of Wnt/β-catenin pathway. Overexpression of the inhibitory genes, particularly SFRP-1 and WIF-1 in BON cells, resulted in suppression of anchorage-independent growth and inhibition of tumor growth in mice. Our findings suggest that aberrant Wnt/β-catenin signaling, through either mutations or epigenetic silencing of Wnt antagonists, contributes to the pathogenesis and growth of NETs and have important clinical implications for the prognosis and treatment of NETs.

AB - Carcinoid tumors are rare neuroendocrine tumors (NETs) that are increasing in incidence. Mutation and altered expression of Wnt/β-catenin signaling components have been described in many tumors but have not been well-studied in NETs. Here, we observed accumulation of β-catenin in the cytoplasm and/or nucleus in 25% of clinical NET tissues. By mutational analysis, the mutations of β-catenin (I35S) and APC (E1317Q, T1493T) were identified in NET cells and the tissues. Expression of representative Wnt inhibitors was absent or markedly decreased in BON, a human pancreatic carcinoid cell line; treatment with 5-aza-2′-deoxycytidine (5-aza-CdR) increased expression levels of the Wnt inhibitors. Methylation analyses demonstrated that CpG islands of SFRP-1 and Axin-2 were methylated, whereas the promoters of DKK-1, DKK-3 and WIF-1 were unmethylated in four NET cells. Aberrant methylation of SFRP-1 was particularly observed in most of clinical NET tissues. In addition, the repression of these unmethylated genes was associated with histone H3 lysine 9 dimethylation (H3K9me2) in BON cells. Together, 5-aza-CdR treatment inhibited cell proliferation and decreased the protein levels of H3K9me2 and G9a. Moreover, a novel G9a inhibitor, UNC0638, suppressed BON cell proliferation through inhibition of Wnt/β-catenin pathway. Overexpression of the inhibitory genes, particularly SFRP-1 and WIF-1 in BON cells, resulted in suppression of anchorage-independent growth and inhibition of tumor growth in mice. Our findings suggest that aberrant Wnt/β-catenin signaling, through either mutations or epigenetic silencing of Wnt antagonists, contributes to the pathogenesis and growth of NETs and have important clinical implications for the prognosis and treatment of NETs.

UR - http://www.scopus.com/inward/record.url?scp=84877118579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877118579&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgt018

DO - 10.1093/carcin/bgt018

M3 - Article

VL - 34

SP - 953

EP - 961

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 5

ER -